Neurogene (NGNE) Common Equity (2013 - 2026)
Neurogene (NGNE) recorded Common Equity of $217.13 million in Q2 2026, down 20.5% from $273.26 million a year earlier and down 8.7% from the prior quarter.
Powered by 
Analysis
Neurogene (NGNE) Common Equity (2013 - 2026) Analysis & Trends
At the end of FY2025, Neurogene reported Common Equity of $264.89 million, down 14.7% from FY2024.
- Annual Common Equity has a five-year compound annual growth rate of 6.7% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $310.38 million in FY2024 (+66.8%), $186.02 million in FY2023, -$145.74 million in FY2022 and -$91.88 million in FY2021.
- The Q2 2026 figure is the lowest quarterly Common Equity since Q3 2024.
- On a year-over-year basis, Common Equity has declined for three consecutive quarters, with growth averaging 36.2% over the last seven quarters.
- Peak year-over-year performance for Common Equity in the last five years was growth of 93.2% in Q3 2025, against a decline of 31.8% in Q3 2022 at the low end.
- Per Business Quant, the preceding three quarters came in at $237.78 million (Q1 2026), $264.89 million (Q4 2025) and $265.54 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,131.80 Bn | 1,100.39 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 614.01 Bn | 532.53 Bn | 17.26 Bn | 84.97 Bn |
| 3 | AbbVie | 503.59 Bn | 476.70 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 367.41 Bn | 321.79 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 297.81 Bn | 261.80 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 261.50 Bn | 235.19 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 236.24 Bn | 191.64 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 191.15 Bn | 165.35 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 170.16 Bn | 116.81 Bn | 10.94 Bn | 85.49 Bn |
| 10 | Neurogene | 575.64 Mn | -427.36 Mn | - | 217.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 217.13 Mn |
| Mar 31, 2026 | 237.78 Mn |
| Dec 31, 2025 | 264.89 Mn |
| Sep 30, 2025 | 265.54 Mn |
| Jun 30, 2025 | 273.26 Mn |
| Mar 31, 2025 | 291.80 Mn |
| Dec 31, 2024 | 310.38 Mn |
| Sep 30, 2024 | 137.41 Mn |
| Jun 30, 2024 | 155.01 Mn |
| Mar 31, 2024 | 170.78 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Sep 30, 2023 | -183.21 Mn |
| Jun 30, 2023 | -169.05 Mn |
| Mar 31, 2023 | -157.60 Mn |
| Dec 31, 2022 | -145.74 Mn |
| Sep 30, 2022 | 105.65 Mn |
| Jun 30, 2022 | 116.71 Mn |
| Mar 31, 2022 | 130.09 Mn |
| Dec 31, 2021 | -91.88 Mn |
| Sep 30, 2021 | 154.87 Mn |
API Access
Neurogene Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=NGNE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "NGNE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=NGNE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();